Keaton S. Smetana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Keaton S. Smetana has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Casey C. May
Department of Pharmacy The Ohio State University Wexner Medical Center Columbus Ohio USA
9 shared publications - Aaron M. Cook
University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science , Lexington, KY
3 shared publications G. Morgan Jones
3 shared publications- G. Morgan Jones
Methodist University Hospital, Memphis, TN, USA
3 shared publications - Megan A. Rech
Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare Edward Hines, Jr. VA Hospital Hines Illinois USA
3 shared publications - Michael J. Erdman
Department of Pharmacy, University of Florida Health, 655 West 8th Street, Jacksonville, FL, 32209, USA
3 shared publications
Latest Publications
- 17 May 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (6) , 586-592
IVIG Administration: Lessons from Cross-Institutional Protocol Review
Background: Intravenous immunoglobulin (IVIG) is used in the acute care, including neurocritical care, setting for a variety of autoimmune and inflammatory conditions. Incidence and severity of infusion-related reactions have been found to be affected by several key factors, including osmolarity, sodium and IgA content, and infusion rate. The purpose of this study was to survey and synthesize IVIG-related practices across various hospitals into a practical guide for clinicians and provide a reference for reviewing or developing IVIG infusion protocols. Methods: Pharmacists from the Neurocritical Care Society Connect online forum were invited to participate in a survey regarding their institutional protocols related to IVIG infusions in the inpatient setting. Results: Data were collected from 12 participating medical centers, all of which have dedicated neurocritical care units. The most common formulation of IVIG used was Privigen ® , followed by Gammagard ® . Gamunex ® -C was only used at two centers. Starting rates for IVIG infusions ranged from 0.3 to 0.6 mL/kg/hr with increases every 15 to 30 minutes. Maximum infusion rates were heterogenous ranging from 2 to 8 mL/kg/hr and often reduced in high-risk populations, such as renal impairment or older age. Significant variation in medication selection and standardization was identified in pre-medication practices and management of adverse reactions. Conclusion: This study highlights the variability in IVIG administration protocols and underscores the need for standardized practices to enhance patient safety and treatment efficacy.
- 17 May 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (6) , 586-592
IVIG Administration: Lessons from Cross-Institutional Protocol Review
Background: Intravenous immunoglobulin (IVIG) is used in the acute care, including neurocritical care, setting for a variety of autoimmune and inflammatory conditions. Incidence and severity of infusion-related reactions have been found to be affected by several key factors, including osmolarity, sodium and IgA content, and infusion rate. The purpose of this study was to survey and synthesize IVIG-related practices across various hospitals into a practical guide for clinicians and provide a reference for reviewing or developing IVIG infusion protocols. Methods: Pharmacists from the Neurocritical Care Society Connect online forum were invited to participate in a survey regarding their institutional protocols related to IVIG infusions in the inpatient setting. Results: Data were collected from 12 participating medical centers, all of which have dedicated neurocritical care units. The most common formulation of IVIG used was Privigen ® , followed by Gammagard ® . Gamunex ® -C was only used at two centers. Starting rates for IVIG infusions ranged from 0.3 to 0.6 mL/kg/hr with increases every 15 to 30 minutes. Maximum infusion rates were heterogenous ranging from 2 to 8 mL/kg/hr and often reduced in high-risk populations, such as renal impairment or older age. Significant variation in medication selection and standardization was identified in pre-medication practices and management of adverse reactions. Conclusion: This study highlights the variability in IVIG administration protocols and underscores the need for standardized practices to enhance patient safety and treatment efficacy.
- 18 March 2025
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 82 (13) , e607-e614
Clearing the air: Assessing inhaler usage and associated greenhouse gas emissions in a health system
Purpose: The transition from chlorofluorocarbons (CFCs) to hydrofluoroalkanes (HFAs) has significantly reduced the greenhouse gas (GHG) emissions associated with metered-dose inhalers (MDIs). However, HFAs still have a high global warming potential (GWP) compared to other alternatives such as dry powder inhalers (DPIs) and soft mist inhalers (SMIs). This transition has significantly impacted GHG emissions, underscoring a need to evaluate the environmental impact of medication delivery via MDIs. Objectives: This study quantifies the GHG emissions, expressed as carbon dioxide equivalents (CO2e), from the use of HFAs in MDIs within our health system. The healthcare system includes 13 hospitals with over 2,000 staffed beds and approximately 100,000 annual patient admissions. It also examines the broader environmental impacts of the packaging materials associated with these inhalers. Methods: A retrospective analysis of the use of albuterol and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) MDIs over a 1-year period, assessing their CO2e emissions and the environmental impact of their packaging. The total weight of propellant was determined by calculating the difference in canister weight before use and after all contents were expelled. Results: A total of 17,589 albuterol and 20,563 ICS/LABA MDIs were dispensed during the study. The total propellant weight led to CO2e emissions of 212 metric tons (MT) for albuterol MDIs and 506 MT for ICS/LABA MDIs. Including resource use and emissions from inhaler components led to an environmental impact that totaled 213 MT of CO2e for albuterol MDIs and 512.5 MT for ICS/LABA MDIs. Conclusion: Our study emphasizes the necessity of integrating environmental stewardship into healthcare practices. By fostering awareness and initiating discussions on sustainable practices, particularly in the context of pharmacy operations, we can contribute to a more environmentally responsible healthcare system while continuing to meet the clinical needs of our patients.
- 18 March 2025
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 82 (13) , e607-e614
Clearing the air: Assessing inhaler usage and associated greenhouse gas emissions in a health system
Purpose: The transition from chlorofluorocarbons (CFCs) to hydrofluoroalkanes (HFAs) has significantly reduced the greenhouse gas (GHG) emissions associated with metered-dose inhalers (MDIs). However, HFAs still have a high global warming potential (GWP) compared to other alternatives such as dry powder inhalers (DPIs) and soft mist inhalers (SMIs). This transition has significantly impacted GHG emissions, underscoring a need to evaluate the environmental impact of medication delivery via MDIs. Objectives: This study quantifies the GHG emissions, expressed as carbon dioxide equivalents (CO2e), from the use of HFAs in MDIs within our health system. The healthcare system includes 13 hospitals with over 2,000 staffed beds and approximately 100,000 annual patient admissions. It also examines the broader environmental impacts of the packaging materials associated with these inhalers. Methods: A retrospective analysis of the use of albuterol and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) MDIs over a 1-year period, assessing their CO2e emissions and the environmental impact of their packaging. The total weight of propellant was determined by calculating the difference in canister weight before use and after all contents were expelled. Results: A total of 17,589 albuterol and 20,563 ICS/LABA MDIs were dispensed during the study. The total propellant weight led to CO2e emissions of 212 metric tons (MT) for albuterol MDIs and 506 MT for ICS/LABA MDIs. Including resource use and emissions from inhaler components led to an environmental impact that totaled 213 MT of CO2e for albuterol MDIs and 512.5 MT for ICS/LABA MDIs. Conclusion: Our study emphasizes the necessity of integrating environmental stewardship into healthcare practices. By fostering awareness and initiating discussions on sustainable practices, particularly in the context of pharmacy operations, we can contribute to a more environmentally responsible healthcare system while continuing to meet the clinical needs of our patients.
- 13 February 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (4) , 362-369
PHarmacist Avoidance or Reductions in Medical Costs Considering Board of Pharmacy Specialties Certification (PHARM-BPS)
Introduction: Clinical pharmacists bring unparalleled medication expertise, but quantifying their impact on a health system’s bottom line remains unestablished. Objective: To classify interventions by pharmacists with and without board certification and quantify the cost avoidance (CA) from accepted interventions. Methods: This multicenter prospective observational study, conducted between August 2018 and January 2019, included board certified (BPS) and non-board certified (Non-BPS) emergency medicine (EM) and intensive care unit (ICU) clinical pharmacists from 89 U.S. institutions. Primary outcomes included the quantity, type, and acceptance of interventions and the CA generated by BPS pharmacists compared to Non-BPS pharmacists. Results: 287 pharmacists (227 BPS, 60 Non-BPS) at 89 centers provided care throughout 4184 shifts. BPS pharmacist provided more interventions (overall: 63 693 vs 8690; per shift: 18.8 vs 10.9, P < .001) with higher acceptance (98.2% vs 97.6%, P < .001). Accepted interventions per shift included adverse drug event prevention (2.0 vs 1.6, P = .17), resource utilization (3.6 vs 1.7, P = .007), individualization of patient care (9.7 vs 5.3, P = .05), prophylaxis (0.4 vs 0.3, P = .99), hands-on care (1.4 vs 0.9, P = .99), and administrative/supportive tasks (1.8 vs 1.1, P = 0.). BPS pharmacists generated greater mean CA per intervention ($873 vs $801), patient day ($961 vs $501), shift ($8112 vs $4828) and annum ($1 946 942 vs $1 158 784) ( P < .001 for all). The CA to salary ratio was 10.5:1 for BPS and 6.3:1 for Non-BPS pharmacists. Conclusion: BPS pharmacists in the ED and ICU generated greater CA and a higher monetary CA to salary ratio than Non-BPS pharmacists.
- 13 February 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (4) , 362-369
PHarmacist Avoidance or Reductions in Medical Costs Considering Board of Pharmacy Specialties Certification (PHARM-BPS)
Introduction: Clinical pharmacists bring unparalleled medication expertise, but quantifying their impact on a health system’s bottom line remains unestablished. Objective: To classify interventions by pharmacists with and without board certification and quantify the cost avoidance (CA) from accepted interventions. Methods: This multicenter prospective observational study, conducted between August 2018 and January 2019, included board certified (BPS) and non-board certified (Non-BPS) emergency medicine (EM) and intensive care unit (ICU) clinical pharmacists from 89 U.S. institutions. Primary outcomes included the quantity, type, and acceptance of interventions and the CA generated by BPS pharmacists compared to Non-BPS pharmacists. Results: 287 pharmacists (227 BPS, 60 Non-BPS) at 89 centers provided care throughout 4184 shifts. BPS pharmacist provided more interventions (overall: 63 693 vs 8690; per shift: 18.8 vs 10.9, P < .001) with higher acceptance (98.2% vs 97.6%, P < .001). Accepted interventions per shift included adverse drug event prevention (2.0 vs 1.6, P = .17), resource utilization (3.6 vs 1.7, P = .007), individualization of patient care (9.7 vs 5.3, P = .05), prophylaxis (0.4 vs 0.3, P = .99), hands-on care (1.4 vs 0.9, P = .99), and administrative/supportive tasks (1.8 vs 1.1, P = 0.). BPS pharmacists generated greater mean CA per intervention ($873 vs $801), patient day ($961 vs $501), shift ($8112 vs $4828) and annum ($1 946 942 vs $1 158 784) ( P < .001 for all). The CA to salary ratio was 10.5:1 for BPS and 6.3:1 for Non-BPS pharmacists. Conclusion: BPS pharmacists in the ED and ICU generated greater CA and a higher monetary CA to salary ratio than Non-BPS pharmacists.
- 28 October 2024
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (2) , 163-168
Exploring Pharmacists’ Perceptions of Text-Based Artificial Intelligence in Resident and Student Education
Introduction: As artificial intelligence (AI) becomes increasingly integrated into various professional fields, understanding its impact on pharmacy education is crucial. This study explores pharmacists’ perceptions of AI’s role in enhancing educational and professional practices, particularly focusing on the generation of educational content and analytical tasks. Objectives: The primary objective was to assess pharmacists’ concerns and perceived benefits regarding the use of AI in pharmacy education, examining variations across different age groups and years of practice. Methods: A cross-sectional survey was completed by 446 pharmacists who actively precept pharmacy residents and students. Respondents practiced across 35 states with over half (53.4%) being in Ohio. The survey included items on concerns about AI’s quality and accuracy, human interaction, plagiarism, and its potential benefits in data analysis and research literature summarization. Responses were analyzed to identify trends across demographic categories, including age and years in practice. Results: Of the respondents, 67.9% expressed concerns about the quality and accuracy of AI-generated content, while 50.9% were concerned about plagiarism. Younger pharmacists (73.8% of those aged 20-29) showed heightened concern about accuracy compared to older groups (56.8% of those aged 60+). In contrast, 57.8% of respondents recognized AI’s potential benefits for data analysis, with experienced pharmacists (>20 years in practice) being more likely to see these advantages (62.2%). Conclusion: The findings indicate a need for targeted educational strategies to address AI literacy and ethical use in pharmacy education. Integrating AI tools that support educational objectives while addressing these concerns could enhance the efficacy and acceptance of AI in pharmacy practice. Further research should explore the development of training programs that align with the evolving expectations and technological competencies of different pharmacist demographics.
- 28 October 2024
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (2) , 163-168
Exploring Pharmacists’ Perceptions of Text-Based Artificial Intelligence in Resident and Student Education
Introduction: As artificial intelligence (AI) becomes increasingly integrated into various professional fields, understanding its impact on pharmacy education is crucial. This study explores pharmacists’ perceptions of AI’s role in enhancing educational and professional practices, particularly focusing on the generation of educational content and analytical tasks. Objectives: The primary objective was to assess pharmacists’ concerns and perceived benefits regarding the use of AI in pharmacy education, examining variations across different age groups and years of practice. Methods: A cross-sectional survey was completed by 446 pharmacists who actively precept pharmacy residents and students. Respondents practiced across 35 states with over half (53.4%) being in Ohio. The survey included items on concerns about AI’s quality and accuracy, human interaction, plagiarism, and its potential benefits in data analysis and research literature summarization. Responses were analyzed to identify trends across demographic categories, including age and years in practice. Results: Of the respondents, 67.9% expressed concerns about the quality and accuracy of AI-generated content, while 50.9% were concerned about plagiarism. Younger pharmacists (73.8% of those aged 20-29) showed heightened concern about accuracy compared to older groups (56.8% of those aged 60+). In contrast, 57.8% of respondents recognized AI’s potential benefits for data analysis, with experienced pharmacists (>20 years in practice) being more likely to see these advantages (62.2%). Conclusion: The findings indicate a need for targeted educational strategies to address AI literacy and ethical use in pharmacy education. Integrating AI tools that support educational objectives while addressing these concerns could enhance the efficacy and acceptance of AI in pharmacy practice. Further research should explore the development of training programs that align with the evolving expectations and technological competencies of different pharmacist demographics.
- 4 January 2024
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 59 (3) , 349-352
Comparing Medication History Capture Rates In-Person Versus Hybrid: A Multisite Pilot Study
Purpose: Medication history is the method many organizations use to adhere to The Joint Commission’s (TJC) National Patient Safety Goal (NPSG) to communicate accurate patient medication information. Literature is sparse comparing the number of medication histories completed in-person versus virtually. Methods: This is a single system, multi-site, retrospective observational study. Patients included were admitted through the Emergency Department during October 2022. The primary aim of this study compared the percent capture rates of medication history between 2 hybrid sites to an in-person site within a health-system. Our secondary objective compared the differences in the ‘medication history acuity score’ (MHAS), defined as the total number of edits, additions, and deletions made during a medication history. Results: The medication history capture rate at the in-person site was 74% and at the hybrid sites were 91% and 80%. There were no differences in total medications on each medication history between in-person and hybrid (11 [5-16] vs 11 [6-16]; P = .252). There were no differences in changes made on medication histories between in-person and hybrid (4 [1-7] vs 3 [1-7]; P = .595). Conclusions: Our study demonstrates that medication history capture rates and MHAS are comparable in both in-person and hybrid environments. This similarity suggests the feasibility of implementing hybrid models for medication history services in diverse healthcare settings, potentially enhancing the capacity of health systems to meet TJC NPSG. These findings indicate that hybrid models could be an effective strategy for healthcare systems to optimize their medication history services, especially in settings with varied patient volumes and site specialties.
- 4 January 2024
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 59 (3) , 349-352
Comparing Medication History Capture Rates In-Person Versus Hybrid: A Multisite Pilot Study
Purpose: Medication history is the method many organizations use to adhere to The Joint Commission’s (TJC) National Patient Safety Goal (NPSG) to communicate accurate patient medication information. Literature is sparse comparing the number of medication histories completed in-person versus virtually. Methods: This is a single system, multi-site, retrospective observational study. Patients included were admitted through the Emergency Department during October 2022. The primary aim of this study compared the percent capture rates of medication history between 2 hybrid sites to an in-person site within a health-system. Our secondary objective compared the differences in the ‘medication history acuity score’ (MHAS), defined as the total number of edits, additions, and deletions made during a medication history. Results: The medication history capture rate at the in-person site was 74% and at the hybrid sites were 91% and 80%. There were no differences in total medications on each medication history between in-person and hybrid (11 [5-16] vs 11 [6-16]; P = .252). There were no differences in changes made on medication histories between in-person and hybrid (4 [1-7] vs 3 [1-7]; P = .595). Conclusions: Our study demonstrates that medication history capture rates and MHAS are comparable in both in-person and hybrid environments. This similarity suggests the feasibility of implementing hybrid models for medication history services in diverse healthcare settings, potentially enhancing the capacity of health systems to meet TJC NPSG. These findings indicate that hybrid models could be an effective strategy for healthcare systems to optimize their medication history services, especially in settings with varied patient volumes and site specialties.
- 26 June 2023
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 58 (6) , 525-526
Implementing In-House Compounding of Nimodipine Oral Syringes for Aneurysmal Subarachnoid Hemorrhage Patients
- 26 June 2023
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 58 (6) , 525-526
Implementing In-House Compounding of Nimodipine Oral Syringes for Aneurysmal Subarachnoid Hemorrhage Patients
- Open Access
- 29 May 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (10) , 1132-1138
Development of 8‐h urine collections and an augmented renal clearance dosing program at an academic medical center
Ensuring appropriate dosing of medications is an essential practice of clinical pharmacists. Dose adjustments in the setting of decreased renal function are common but may also be warranted for patients with supraphysiologic or augmented renal clearance (ARC). Conventional estimates of creatinine clearance using only serum creatinine may not be accurate in the setting of ARC, thus a measured creatinine clearance using serum and urine creatinine measurements are preferred. We describe the development of an 8‐h urine collection and ARC dosing program at a large academic medical center initiated by critical care and infectious disease pharmacists. Using a Plan–Do–Study–Act approach, we implemented and updated the 8‐h collection program with the guidance of our clinical laboratories. Eight‐hour urine collections are useful for patients with suspected ARC and for other scenarios where accurate dose adjustments are needed to minimize toxicity in the absence of therapeutic drug monitoring.
- 29 May 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (10) , 1132-1138
Open AccessDevelopment of 8‐h urine collections and an augmented renal clearance dosing program at an academic medical center
Ensuring appropriate dosing of medications is an essential practice of clinical pharmacists. Dose adjustments in the setting of decreased renal function are common but may also be warranted for patients with supraphysiologic or augmented renal clearance (ARC). Conventional estimates of creatinine clearance using only serum creatinine may not be accurate in the setting of ARC, thus a measured creatinine clearance using serum and urine creatinine measurements are preferred. We describe the development of an 8‐h urine collection and ARC dosing program at a large academic medical center initiated by critical care and infectious disease pharmacists. Using a Plan–Do–Study–Act approach, we implemented and updated the 8‐h collection program with the guidance of our clinical laboratories. Eight‐hour urine collections are useful for patients with suspected ARC and for other scenarios where accurate dose adjustments are needed to minimize toxicity in the absence of therapeutic drug monitoring.
- 7 May 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (9) , 1000-1007
PHarmacist avoidance or reductions in medical costs in CRITically ill adults rounding with one SERVICE compared to two or more services: PHARM‐CRIT‐SERVICE
Introduction: Intensive care unit (ICU) pharmacists are integral members of the interdisciplinary health care team. Pharmacy staffing models vary by ICU and hospital, and clinical pharmacists may cover one ICU service or multiple services. It is presently unknown how covering or rounding on multiple services relative to one service impacts the quantity of interventions made or the acceptance rate of those interventions.Methods: Exploratory analysis of the PHarmacist Avoidance or Reductions in Medical costs in CRITically ill adults (PHARM‐CRIT) study, a multicenter, prospective, observational study was performed between August 2018 and January 2019 in academic medical centers and community hospitals throughout the United States. ICU pharmacists documented recommendations and accepted interventions. Pharmacists that covered one service were compared to those who covered two or more services or no services.Results: 218 ICU pharmacists participated across 85 centers. There were 2905 shifts and the primary rounding structure was one service (n = 1766, 60.8%) compared to covering two or more services (n = 822, 28.3%), and no rounding (n = 317, 10.9%). The percent of pharmacists with accepted interventions was higher with one service compared to the other groups: one service (45.7% ± 1.8) vs. no rounding (12.7% ± 1) (odds ratio [OR] 4.92 [95% confidence interval (CI) 4.19–5.78]) and one service vs. two or more services (31.6% ± 1.6) (OR 1.81 [95% CI 1.67–1.95]). This was also observed when comparing two or more services to no rounding (OR 2.73 [95% CI 2.32–3.2]). The probability of an intervention being accepted was highest in pharmacists rounding on one service, followed by two or more services, and least likely without rounding. Increasing the patient load of the pharmacist in any of the rounding structures resulted in a decline in interventions being accepted.Conclusions: ICU pharmacists rounding with one service relative to two or more or none had more interventions attempted and accepted.
- 7 May 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (9) , 1000-1007
PHarmacist avoidance or reductions in medical costs in CRITically ill adults rounding with one SERVICE compared to two or more services: PHARM‐CRIT‐SERVICE
Introduction: Intensive care unit (ICU) pharmacists are integral members of the interdisciplinary health care team. Pharmacy staffing models vary by ICU and hospital, and clinical pharmacists may cover one ICU service or multiple services. It is presently unknown how covering or rounding on multiple services relative to one service impacts the quantity of interventions made or the acceptance rate of those interventions.Methods: Exploratory analysis of the PHarmacist Avoidance or Reductions in Medical costs in CRITically ill adults (PHARM‐CRIT) study, a multicenter, prospective, observational study was performed between August 2018 and January 2019 in academic medical centers and community hospitals throughout the United States. ICU pharmacists documented recommendations and accepted interventions. Pharmacists that covered one service were compared to those who covered two or more services or no services.Results: 218 ICU pharmacists participated across 85 centers. There were 2905 shifts and the primary rounding structure was one service (n = 1766, 60.8%) compared to covering two or more services (n = 822, 28.3%), and no rounding (n = 317, 10.9%). The percent of pharmacists with accepted interventions was higher with one service compared to the other groups: one service (45.7% ± 1.8) vs. no rounding (12.7% ± 1) (odds ratio [OR] 4.92 [95% confidence interval (CI) 4.19–5.78]) and one service vs. two or more services (31.6% ± 1.6) (OR 1.81 [95% CI 1.67–1.95]). This was also observed when comparing two or more services to no rounding (OR 2.73 [95% CI 2.32–3.2]). The probability of an intervention being accepted was highest in pharmacists rounding on one service, followed by two or more services, and least likely without rounding. Increasing the patient load of the pharmacist in any of the rounding structures resulted in a decline in interventions being accepted.Conclusions: ICU pharmacists rounding with one service relative to two or more or none had more interventions attempted and accepted.
- 24 January 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (8) , 848-855
Evaluation of an electronic health record documentation tool use to improve pharmacist intervention tracking in the intensive care unit
Purpose: Pharmacists are integral members of the healthcare team, but interventions are not always captured due to documentation limitations. This study evaluated the impact of implementing a tracking tool to address gaps in capturing pharmacist interventions.Methods: A prospective, observational study was conducted to assess pharmacist interventions between July and November 2020. Twelve critical care pharmacists captured interventions on 10 weekdays using a tracking tool (iVent—Epic®) embedded in the electronic medical record (EMR) to capture high frequency interventions not standardly captured via existing standard note documentation (e.g., renal/hepatic dose adjustment, parenteral nutrition management). Value added of the interventions is proposed. Patients' baseline demographics, interventions, Sequential Organ Failure Assessment (SOFA) score, and intensive care unit (ICU) length of stay (LOS) were collected. The primary outcome was to determine the added benefit of using a tracking tool within the EMR to capture pharmacist interventions compared to progress note documentation.Results: Two thousand seven hundred and eighty‐three interventions were documented on 514 unique patients over 120 pharmacist shifts. Of these, 2363 (84.9%) interventions were captured through iVent tracking. The median SOFA score on day of intervention was 4 [interquartile range (IQR) 2–7] and ICU LOS was 3.5 days [IQR 1.5–9]. The median number of interventions per patient per day was 2 [IQR 1–3]. A significant difference was observed among days of the week and the number of iVents documented (χ2 = 13.172, p = 0.01, df = 4). The post hoc pairwise comparison revealed more documented iVents on Tuesday than Friday.Conclusion: This study reveals that an iVent tracking tool increased total capture of pharmacist interventions by 563%. These interventions can be associated with value‐based programs and further work is needed in highlighting the pharmacist's role in these new payment models. This study confirms that the current standard practice at this institution of solely entering pharmacist progress notes into the patient chart misses a majority of pharmacist interventions.
- 24 January 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (8) , 848-855
Evaluation of an electronic health record documentation tool use to improve pharmacist intervention tracking in the intensive care unit
Purpose: Pharmacists are integral members of the healthcare team, but interventions are not always captured due to documentation limitations. This study evaluated the impact of implementing a tracking tool to address gaps in capturing pharmacist interventions.Methods: A prospective, observational study was conducted to assess pharmacist interventions between July and November 2020. Twelve critical care pharmacists captured interventions on 10 weekdays using a tracking tool (iVent—Epic®) embedded in the electronic medical record (EMR) to capture high frequency interventions not standardly captured via existing standard note documentation (e.g., renal/hepatic dose adjustment, parenteral nutrition management). Value added of the interventions is proposed. Patients' baseline demographics, interventions, Sequential Organ Failure Assessment (SOFA) score, and intensive care unit (ICU) length of stay (LOS) were collected. The primary outcome was to determine the added benefit of using a tracking tool within the EMR to capture pharmacist interventions compared to progress note documentation.Results: Two thousand seven hundred and eighty‐three interventions were documented on 514 unique patients over 120 pharmacist shifts. Of these, 2363 (84.9%) interventions were captured through iVent tracking. The median SOFA score on day of intervention was 4 [interquartile range (IQR) 2–7] and ICU LOS was 3.5 days [IQR 1.5–9]. The median number of interventions per patient per day was 2 [IQR 1–3]. A significant difference was observed among days of the week and the number of iVents documented (χ2 = 13.172, p = 0.01, df = 4). The post hoc pairwise comparison revealed more documented iVents on Tuesday than Friday.Conclusion: This study reveals that an iVent tracking tool increased total capture of pharmacist interventions by 563%. These interventions can be associated with value‐based programs and further work is needed in highlighting the pharmacist's role in these new payment models. This study confirms that the current standard practice at this institution of solely entering pharmacist progress notes into the patient chart misses a majority of pharmacist interventions.
- 2 January 2023
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (3) , 587-592
Characterization of Medication Discrepancies and Interventions Resulting From Pharmacy-Led Medication Reconciliation in the Critical Care Setting
Background: Medication reconciliation has been shown to reduce medication-related errors in hospitalized patients, but the impact of pharmacy-led medication reconciliation in the intensive care unit (ICU) has not been extensively studied. Methods: This was a retrospective chart review of patients with a pharmacy-led medication reconciliation on admission to an ICU between January 1st and March 31st, 2018. Pharmacy-led medication reconciliations were completed by pharmacists, pharmacy residents, and pharmacy students. The objective of this study was to describe medication discrepancies identified by pharmacy-led medication reconciliation and to evaluate the interventions following. Results: A total of 288 patients were screened and 247 met inclusion criteria. There were 1148 medication discrepancies identified resulting in an average of 4.65 discrepancies per patient. Medication addition (54.25%) and medication deletion (45.75%) were most common. Within 24 hours of medication reconciliation, 214 interventions were made to active orders. No differences were observed between discrepancies identified and type of pharmacy staff completing the medication reconciliation. Conclusions: This study identified a high rate of medication discrepancies on admission to the ICU. Furthermore, it describes the types of pharmacist interventions following pharmacy-led medication reconciliation. This process may be impactful to incorporate as a standard practice in ICUs and warrants further investigation into value, cost, and pharmacist workflow.
- 2 January 2023
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (3) , 587-592
Characterization of Medication Discrepancies and Interventions Resulting From Pharmacy-Led Medication Reconciliation in the Critical Care Setting
Background: Medication reconciliation has been shown to reduce medication-related errors in hospitalized patients, but the impact of pharmacy-led medication reconciliation in the intensive care unit (ICU) has not been extensively studied. Methods: This was a retrospective chart review of patients with a pharmacy-led medication reconciliation on admission to an ICU between January 1st and March 31st, 2018. Pharmacy-led medication reconciliations were completed by pharmacists, pharmacy residents, and pharmacy students. The objective of this study was to describe medication discrepancies identified by pharmacy-led medication reconciliation and to evaluate the interventions following. Results: A total of 288 patients were screened and 247 met inclusion criteria. There were 1148 medication discrepancies identified resulting in an average of 4.65 discrepancies per patient. Medication addition (54.25%) and medication deletion (45.75%) were most common. Within 24 hours of medication reconciliation, 214 interventions were made to active orders. No differences were observed between discrepancies identified and type of pharmacy staff completing the medication reconciliation. Conclusions: This study identified a high rate of medication discrepancies on admission to the ICU. Furthermore, it describes the types of pharmacist interventions following pharmacy-led medication reconciliation. This process may be impactful to incorporate as a standard practice in ICUs and warrants further investigation into value, cost, and pharmacist workflow.